EGFR and breast cancer: The hybridizing pyrazoline and thiazole scaffolds has proven effective in developing novel conjugates with targeted anticancer properties, including EGFR-specific activity against NSCLC and/or breast cancer (Figure 3) [31,32,33,34,35,36].